Page 517 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

Chapter 36

REFERENCES

1. Vos MA LB. Automaticity and Triggered Activity. Foundations of 15. McGavin JK, Keating GM. Bisoprolol: a review of its use in
Cardiac Arrhythmias: Basic Concepts and Clinical Approaches. chronic heart failure. Drugs. 2002;62(18):2677-2696.
Marcel Dekker Inc; New York, NY. 2001:425-448. 16. Gillis AM, Wyse DG. Supraventricular tachycardia. In: Gray JD,
2. Janse MJ, Dorinar E. Reentry. In: Spooner PM, Rosen MR, eds. ed. Therapeutic Choices. 4th ed. Ottawa, ON: Canadian
Foundations of Cardiac Arrhythmias: Basic Concepts and Clinical Pharmacists Association; 2003:330-345.
Approaches. Marcel Dekker Inc; New York, NY. 2001:449-478 17. Dorian P. Ventricular tachyarrhythmias. In: Gray JD, ed.
3. Zipes DP. Mechanisms of clinical arrhythmias. J Cardiovasc Therapeutic Choices. 4th ed. Ottawa, ON: Canadian Pharmacists
Electrophysiol. 2003;14(8):902-912. Association; 2003.
4. Roden DM. Antiarrhythmic drugs: from mechanisms to clinical 18. Zhou SF. Polymorphism of human cytochrome P450 2D6 and
practice. Heart. 2000;84(3):339-346. its clinical significance: part I. Clin Pharmacokinet. 2009;48(11):
5. Members of the Sicilian Bambin. New approaches to antiarrhyth- 689-723.
mic therapy, part I: emerging therapeutic applications of the 19. Kannankeril PJ. Understanding drug-induced torsades de
cell biology of cardiac arrhythmias. Circulation. 2001;104(23): pointes: a genetic stance. Expert Opin Drug Saf. 2008;7(3):
2865-2873. 231-239.
6. Gillis AM. Class I antiarrhythmic drugs. In: Zipes DP, Jalife J, 20. Myerburg RJ. Scientific gaps in the prediction and prevention
eds. Cardiac Electrophysiology: From Cell to Bedside. 4th ed. of sudden cardiac death. J Cardiovasc Electrophysiol. 2002;13(7):
Philadelphia, PA: WB Sauders and Co; 2004:911-917. 709-723.
7. Gillis AM. Proarrhythmia syndromes. In: Camm AJ, Saksena 21. Gillis AM, Hamilton RM, LeFeuvre CA. Unusual causes of sud-
S, eds. Electrophysiological Disorders of the Heart. 2nd ed. den cardiac death due to ventricular tachyarrhythmias. Can J
Philadelphia, PA: WB Saunders and Co; 2004:501-516. Cardiol. 2000;16(suppl C):34C-40C.
8. Dorian P. Mechanisms of action of class III agents and their 22. Connolly SJ, Krahn A, Klein G. Long term management of
clinical relevance. Europace. 2000;1(suppl C):C6-C9. the survivor of ventricular fibrillation or sustained ventricular
9. Pamukcu B, Lip GY. Dronedarone as a new treatment option tachycardia. Can J Cardiol. 2000;16(suppl C):20C-22C.
for atrial fibrillation patients: pharmacokinetics, pharmaco- 23. Grogin HR, Scheinman M. Evaluation and management of
dynamics and clinical practice. Expert Opin Pharmacother. patients with polymorphic ventricular tachycardia. Cardiol Clin.
2011;12(1):131-40. 1993;11(1):39-54.
10. Singh BN. β-blockers and calcium channel blockers as 24. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecu-
antiarrhythmic drugs. In: Zipes DP, Jalife J, eds. Cardiac lar characterization of patients with catecholaminergic polymor-
Electrophysiology: From Cell to Bedside. 4th ed. Philadelphia, PA: phic ventricular tachycardia. Circulation. 2002;106(1):69-74.
WB Saunders and Co; 2004:918-9931. 25. Gillis AM. Intractable ventricular arrhythmias: immediate
11. Roden DM. Mechanisms and management of proarrhythmia. evaluation and management, role of pharmacological therapy.
Am J Cardiol. 1998;82(4A):49I-57I. Card Electrophysiol Rev. 2001;3(2):145-148.
12. Roden DM. Antiarrhythmic drugs. In: Hardman JG, Limbird LE, 26. Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced
eds. Goodman and Gilman’s The Pharmacological Basis of cardiovascular life support: 2010 American Heart Asso-
Therapeutics. 10th ed. New York, NY: McGraw-Hill; 2001: ciation Guidelines for Cardiopulmonary Resuscitation and
933-970. Emergency Cardiovascular Care. Circulation. 2010;122(18 suppl
13. Wilkinson GR. Pharmacokinetics. In: Hardman JG, Limbird LE, 3):S729-S767.
eds. Goodman and Gilman’s The Pharmacological Basis of 27. Link MS, Atkins DL, Passman RS, et al. Part 6: electrical therapies:
Therapeutics. 10th ed. New York: McGraw-Hill; 2001:3-29. automated external defibrillators, defibrillation, cardioversion,
14. Wadworth AN, Murdoch D, Brogden RN. Atenolol: a reap- and pacing: 2010 American Heart Association Guidelines for
praisal of its pharmacological properties and therapeutic use in Cardiopulmonary Resuscitation and Emergency Cardiovascular
cardiovascular disorders. Drugs. 1991;42(3):468-510. Care. Circulation. 2010;122(18 suppl 3):S706-S719.

Section03-O-ref.indd 1 1/20/2015 7:10:22 AM